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Introduction
Barrett’s esophagus (BE) is the only identifiable premalignant
condition for esophageal adenocarcinoma (EAC), a malignancy
associated with a dismal 5-year survival rate of < 15% and in-
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Background Conflicting data exist with regard to recur-
rence rates of intestinal metaplasia (IM) and dysplasia after
achieving complete eradication of intestinal metaplasia
(CE-IM) in Barrett’s esophagus (BE) patients.
Aim (i) To determine the incidence of recurrent IM and
dysplasia achieving CE-IM and (ii) to compare recurrence
rates between treatment modalities [radiofrequency abla-
tion (RFA) with or without endoscopic mucosal resection
(EMR) vs stepwise complete EMR (SRER)].
Methods A systematic search was performed for studies
reporting on outcomes and estimates of recurrence rates
after achieving CE-IM. Pooled incidence [per 100-patient-
years (PY)] and risk ratios with 95%CI were obtained. Het-
erogeneity was measured using the I2 statistic. Subgroup
analyses, decided a priori, were performed to explore het-
erogeneity in results.
Results A total of 39 studies were identified (25-RFA, 13-
SRER, and 2 combined). The pooled incidence of any recur-
rence was 7.5 (95%CI 6.1–9.0)/100 PY with a pooled inci-
dence of IM recurrence rate of 4.8 (95%CI 3.8–5.9)/100
PY, and dysplasia recurrence rate of 2.0 (95%CI 1.5–2.5)/
100 PY. Compared to the SRER group, the RFA group had
significantly higher overall [8.6 (6.7–10.5)/100 PY vs. 5.1
(3.1–7)/100 PY, P=0.01] and IM recurrence rates [5.8
(4.3–7.3)/100 PY vs. 3.1 (1.7–4)/100 PY, P <0.01] with no
difference in recurrence rates of dysplasia. Significant het-
erogeneity between studies was identified. The majority of
recurrences were amenable to repeat endoscopic eradica-
tion therapy (EET).
Conclusion The results of this study demonstrate that the
incidence rates of overall, IM, and dysplasia recurrence
rates post-EET are not inconsiderable and reinforce the im-
portance of close surveillance after achieving CE-IM.
* Results of this study were presented in part at Digestive Disease Week
2015, Washington, DC, USA
** Drs Fujii-Lau and Cinnor contributed equally to this manuscript and are
joint first authors.
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creasing annual incidence [1–7]. BE is believed to affect 1–2%
of the general population and is characterized by replacement
of normal squamous epithelium of the distal esophagus by a
columnar lined esophagus [8–10]. Malignant transformation
of BE to EAC is thought to occur in a stepwise and probabilistic
fashion through the histopathologic stages of low grade dys-
plasia (LGD), then high grade dysplasia (HGD) which in turn
gives rise to intramucosal carcinoma and eventually progresses
to invasive adenocarcinoma [11–15].
This pathway of BE to invasive EAC provides an opportunity
to halt the progression and decrease the incidence and preval-
ence of Barrett’s related EAC and ultimately impact the morbid-
ity and mortality related to this lethal cancer. To this end, var-
ious endoscopic eradication therapies (EET) have been evaluat-
ed over the years. Advances in this field have resulted in a sig-
nificant decline in patients referred for esophagectomy with
comparable outcomes (EAC free survival) reported in BE pa-
tients with HGD and mucosal EAC treated with esophagectomy
and EET [16–19]. Two of such EETs that are widely used alone
or in combination are endoscopic mucosal resection (EMR)
and radiofrequency ablation (RFA). Efficacy data from two ran-
domized controlled trials have shown that RFA decreases the
risk of neoplastic progression among patients with BE-associat-
ed HGD and LGD [20, 21]. Recently, data from the US multicen-
ter RFA Patient Registry that included BE patients treated with
RFA showed that 0.2% (0.7/1000 person-years) died from EAC
[22]. Current contemporary management of BE-related neopla-
sia involves EMR of any visible lesion (if present) followed by ab-
lation of the remaining Barrett’s segment. The current goal of
EET is not only to achieve complete eradication of dysplasia/
neoplasia (CE-D; including intramucosal EAC, HGD and LGD)
but also complete eradication of intestinal metaplasia (CE-IM)
given the 30% risk of metachronous neoplasia [23, 24].
The effectiveness of both techniques (EMR and RFA) in
achieving CE-IM and CE-D has been demonstrated in multiple
studies. Reported CE-D and CE-IM rates for EMR are in the
ranges 82–100% and 72–97%, respectively [25–29], and
those for RFA with and without EMR are in the ranges 83–93%
and 78–93%, respectively [30–33]. In addition, available data
indicate that most patients maintain the status of CE-IM [30,
32, 33]. The high efficacy rate of EET in eradicating BE-related
neoplasia and maintaining remission has revolutionized the
management of these patients avoiding the morbidity and
mortality associated with esophagectomy. However, the focus
has now shifted to the durability of EET. Patients with BE-relat-
ed neoplasia undergoing EET and achieving CE-IM are at per-
sistent risk for recurrent IM and dysplasia; however, precise es-
timates of recurrence rates are not available. Widely variable re-
currence rates have been reported after CE-IM in patients un-
dergoing EMR alone [26–29], as well as RFA with or without
EMR (dysplasia: 0–15%, IM: 7–39.5%) [30, 33–36].
The absence of a reliable estimate of recurrence rates has
made it difficult to inform patients as to the expected out-
comes with EET. Additionally, guidelines with regard to surveil-
lance and the interval of surveillance for patients who have
achieved CE-IM following EET currently rely on expert opinion.
To this end, the aim of this systematic review and meta-analysis
was to determine the incidence of recurrence of IM and dyspla-
sia post CE-IM for patients with BE treated with EET (EMR, RFA
or a combination of both).
Materials and methods
This systematic review and meta-analysis was performed and
reported according to the recommendations of the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) criteria [37].
Search strategy
Three databases (MEDLINE PubMed, EMBASE, and Web of Sci-
ence) were systematically searched (by author LLFL) for rele-
vant articles from 1996 through 31 May 2016. Keywords used
in the search included a combination of “Barrett’s esophagus,
Barrett’s oesophagus, recurrence, response, eradication, out-
comes, complete, endoscopic ablation, radiofrequency abla-
tion, endoscopic resection, endoscopic mucosal resection, sub-
squamous Barrett’s, subsquamous intestinal metaplasia.” Re-
ference lists of pertinent articles, including the selected studies
for inclusion, reviews, and practice guidelines, were also manu-
ally searched to identify any other potentially relevant articles.
Relevant abstracts identified by EMBASE from the major gastro-
enterology conferences including Digestive Disease Week,
American College of Gastroenterology, and United European
Gastroenterology published within the past 5 years were also
included.
Study inclusion and exclusion criteria and
definitions
Each abstract identified by the search strategy was reviewed by
two independent authors (LLFL and BC) for possible inclusion in
the study. Full text manuscripts were obtained and evaluated
for those that were potentially relevant after abstract review.
Studies were included if they met the following strict criteria:
(1) study design – randomized control trial, cohort studies,
case series with at least 20 patients; (2) patient population –
patients who achieved CE-IM after endoscopic therapy of Bar-
rett’s esophagus with IM, dysplasia or early adenocarcinoma
(EAC); (3) intervention – primary endoscopic therapy with step-
wise complete endoscopic resection (SRER) or radiofrequency
ablation (RFA) with or without focal endoscopic mucosal resec-
tion (EMR); (4) outcome – reported number of patients with re-
current IM, dysplasia, or EAC on histology; and (5) mean follow-
up of at least 1 year after the first endoscopy confirming com-
plete eradication. The definition of CE required both endo-
scopic and pathologic absence of IM and dysplasia during at
least one endoscopic evaluation after EET. Recurrence was de-
fined by the presence of IM and/or dysplasia in the esophagus
and/or gastroesophageal junction/cardia after achieving CE-
IM. IM obtained on biopsies of the gastric cardia alone (sepa-
rate from gastroesophageal junction biopsies) was not consid-
ered a recurrence.
Studies were excluded from the final analysis if any of the
following was present: (1) study design of case– control, case
series with less than 20 patients, case reports, cross-sectional
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studies, editorials, letters to the editor, reviews, book chapters;
(2) a patient population which did not have pathologic confir-
mation (of the initial histologic reading before EET and recur-
rence) by a second or specialized pathologist, the manuscript
did not specify how many patients failed endoscopic therapy
(did not achieve CE-IM) or required surgical treatment; (3)
other forms of primary endoscopic therapy including cryother-
apy, photodynamic therapy, argon plasma coagulation; (4)
studies with insufficient data to estimate an incidence of recur-
rence; (5) non-English reports; (6) non-human or non-clinical
studies; and (7) duplicate reports. In the event where multiple
manuscripts included the same cohort of patients, the study
with the longest mean follow-up interval was included.
Data abstraction
Data extraction using standardized forms was independently
performed by two investigators (LLFL and BC). Any disagree-
ment over the extracted data was resolved by consensus (LLFL,
BC and SW). The following data were collected from each study:
(1) study characteristics– design (cohort, randomized control
trial, case series), outlook (retrospective, prospective), setting
(single center or multicenter), tertiary centers vs community,
location (USA vs non-USA); (2) patient characteristics– demo-
graphics (mean age, proportion of males, average maximal BE
length, highest pretreatment histological grade), total number
of patients who underwent EET, proportion of patients with fol-
low-up for at least 1 year, if and how patients who were lost to
follow-up were accounted for; (3) treatment characteristics–
primary endoscopic treatment with SRER or RFA with or with-
out focal EMR, definition of CE; (4) surveillance methodology–
whether the neo-gastroesophageal junction/gastric cardia was
biopsied separately, biopsy methods (1- or 2-cm intervals; if
the study allowed biopsies every 1–2 cm, it was included in
the 2-cm cohort); and (5) outcomes data including mean or
median length of follow-up for the study (years) and number
of events of recurrent IM, dysplasia and EAC. If a study included
patients who had more than one surveillance upper endoscopy
with recurrent IM or dysplasia, only the first endoscopy demon-
strating recurrence was included.
Study quality assessment
Quality assessment of each study was independently reviewed
by the same two investigators using the Downs and Black qual-
ity assessment checklist [38]. This instrument was chosen as it
has been validated and assesses both randomized and non-ran-
domized (observational) studies. If recurrence after EET was a
secondary objective of the manuscript and was only reported
as a descriptive analysis, then the study was designated of low
quality to answer the aim of this meta-analysis. As recurrence
was not considered to be a main outcome in these studies, a
“0” was given to the following criteria that focused on the
main finding: (1) are the distributions of principal confounders
in each group of subjects to be compared clearly described, (2)
does the study provide estimates of the random variability in
the data for the main outcome, (3) have actual probability val-
ues been reported for the main outcome, (4) were the statisti-
cal tests used to assess the main outcomes appropriate, (5)
were the main outcome measures used accurate, (6) was there
adequate adjustment for confounding in the analysis from
which the main findings were drawn, and (7) did the study
have sufficient power to detect a clinically important effect
where the probability value for a difference being due to
change is < 5%. Scores < 15, 15–19, and >20 were considered
to be low, moderate, and high quality studies, respectively. All
abstracts and case series were considered to be of low quality.
Outcomes assessed
The primary analysis focused on the pooled incidence [per 100
patient years (PY)] of IM and early neoplasia (a combination of
both dysplasia and EAC for this analysis) in patients achieving
CE-IM after EET. Subgroup analyses were performed for hy-
potheses determined a priori that may explain potential hetero-
geneity between the included studies. The subgroup analyses
designated a priori were type of report (abstract vs full text),
study outlook (prospective vs retrospective), study setting (sin-
gle center vs multicenter), hospital type (solely tertiary centers
vs mixed), study location (USA vs non-USA), quality (divided
into high, medium and low), type of EET (SRER vs RFA with or
without EMR), whether non-dysplastic BE patients were includ-
ed in the treatment group, CE definition (classified as 1 vs 2
negative endoscopies), whether the neo-squamous gastro-
esophageal junction/gastric cardia was biopsied separately dur-
ing surveillance examinations, length intervals of surveillance
biopsies (1 vs 2 cm; studies that allowed biopsies every 1–2 cm
were classified in the latter group), and length of Barrett’s seg-
ment (≤3 cm vs >3 cm). A cutoff of 3 cm was used for BE length
as most studies used this to differentiate between short and
long segment BE. Due to the variability in reporting on contin-
uous variables such as BE length, changing the variable to a bi-
nary variable was deemed to be the most appropriate method
to include the maximum number of studies in this analysis.
Statistical analysis
All analyses and graphs were performed using Comprehensive
Meta-Analysis Version 2 or 3 (Biostat, Englewood, NJ, United
States). The random effects model, as described by DerSimo-
nian and Laird, was used for all analyses to determine incidence
of recurrence (number of events per 100 PY) with the 95% con-
fidence intervals (CI) [39]. Heterogeneity was assessed using
the I2 statistic, with a value >50 considered significant for het-
erogeneity and was the reason we used the random effects
model. Sensitivity analysis was performed to determine wheth-
er a single study had significant influence on the results, focus-
ing on the total recurrences for both IM and dysplasia. Publica-
tion bias was assessed using a funnel plot with event rate plot-
ted against standard error Egger’s regression intercept (P val-
ues ≤0.10 suggestive of significant publication bias). Descrip-
tive analyses were used for the risk of recurrence given the
small number of studies reporting this information and the het-
erogeneity of the risk factors included.
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Results
Characteristics of included studies
From the original search, of the 3311 identified studies, 3167
were excluded based on the title and abstract alone (▶Fig. 1).
The full-text of the remaining 144 studies was reviewed and an
additional 111 studies were excluded. We updated our search
for eligible studies after the 2016 Digestive Disease Week con-
ference and identified three more abstracts that met our
study’s inclusion and exclusion criteria. A total of 39 studies
(33 full-text manuscripts and 6 abstracts) were included in the
final analysis. The two groups in a randomized controlled trial
comparing SRER to RFA with focal EMR were treated as separate
patient cohorts in this analysis [34].
The overall study and patient characteristics are highlighted
in ▶Table1 and ▶Table 2, respectively. A total of 25 studies fo-
cused on RFA with or without EMR, 13 studies described out-
comes in patients treated with SRER as the primary EET modal-
ity (1 study compared both RFA and SRER), and 2 abstracts
combined both SRER and RFA in their analysis. Of the manu-
scripts focusing on RFA, 1 was a randomized controlled trial,
19 cohort observational studies, and 5 case series. Two cohort
studies were included in only the recurrent dysplasia analysis as
they did not report how many patients had recurrent IM [40,
41]. The distribution of studies based on geographic location
was as follows: USA (23), Europe (13), Australia (2), and Canada
(1). Overall, 4355 patients (3213 treated with RFA, 567 with
SRER, and 575 both modalities) were included in the analysis
for a total of 11 837.63 patient-years of follow-up.
Quality of the included studies
In all of the included randomized controlled trials and cohort
studies, the main objective, intervention of interest, and main
findings were clearly described. Of the 18 full text randomized
controlled trials or cohort studies, 4 were considered to be of
high quality (3 RFA, 1 SRER), 7 moderate quality (6 RFA studies,
and 1 study comparing RFA to SRER), and 7 low quality (7 RFA)
as highlighted in ▶Supplemental Table 1. The majority of the
moderate and low quality studies reported recurrence after EET
as a secondary analysis; only 7 cohort full text studies (6 RFA
and 1 SRER) had recurrence as the primary outcome [27, 32,
35, 36, 42–44]. The 16 case series and 5 cohort abstracts were
all considered to be low quality.
Incidence of recurrence
Overall, a total of 1000 recurrences occurred after CE-IM, of
which 722 occurred after RFA, 103 after SRER therapy, and
175 after either therapy. Overall, the pooled incidence of any
recurrence was 7.5 (95%CI 6.1–9)/100 PY (▶Fig. 2a), recur-
rence of IM was 4.8 (3.8–5.9)/100 PY (▶Fig. 2b), and recur-
rence of dysplasia was 2.0 (1.5–2.5)/100 PY (▶Fig. 2c). The to-
tal recurrence does not equal the combination of both IM and
dysplasia recurrence as some studies only reported on either
IM or dysplasia recurrence and these were not included in the
total recurrences.
The IM and dysplasia recurrence rates for the RFA and SRER
groups are highlighted in ▶Table3. Compared to the SRER
group, the RFA group had significantly higher overall [8.6
(6.7–10.5)/100 PY vs 4.9 (3–6.8)/100 PY, P=0.007] and IM re-
currence rates [5.8 (4.3–7.3)/100 PY vs 3.3 (2–4.7)/100 PY, P
=0.015]. However, there was no difference in the recurrence
rate of dysplasia between the two groups [1.9 (1.3–2.5)/100
PY in the RFA vs 1.2 (0.4–1.9)/100 PY in the SRER group, P=
0.11]. The majority of recurrences were amenable to repeat
EET as highlighted in ▶Table 4.
Subgroup analyses on incidence of recurrence
Significant heterogeneity between studies was identified, with
an overall I2 value of 86. To explore the potential causes of
this heterogeneity, several subgroup analyses were per-
formed. In the RFA group, significant factors associated with
a higher IM recurrence rate included retrospective study de-
sign, inclusion of abstracts, surveillance biopsy protocol and
BE length of ≤3 cm (▶Table5). Similar subgroup analyses per-
formed in the SRER group are highlighted in ▶Table 6.
3111 studies identified during systematic search
144 full-text articles reviewed
39* studies included
24 RFA, 12 SRER, 1 compared RFA and SRER, 
2 combined
3167 excluded:
1173- lack of relevance (not BE)
1087- review/meta-analysis
300- lack of relevance (BE studies)
290- case report, letters, editorial
148- basic science
96- other primary endoscopic therapy
41- irrelevant abstract
20- study of other visualization techniques
15- duplicate 
111 excluded:
1- lack of relevance (not BE)
6- review/meta-analysis
32- lack of relevance (BE studies)
8- case report, letters, editorial
12- other primary endoscopic therapy
1- irrelevant abstract
15- duplicate patient population
20- <20 patients included in case series
10- inadwquate follow-up
6- abstracts not able to retrieve, >5 years,
not from a major GI conference 
▶ Fig. 1 Study flow diagram. *133 full text studies and 6 abstracts.
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IM 2 No 1
Alvarez Herrero
et al., 2011 [53]
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Europe Low L,H,EAC 1 Yes 2
Shaheen et al.,
2011 [30]
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Vaccaro et al.,
2011 [36]
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van Vilsteren et
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H,EAC 1 Yes 2
Caillol et al.,
2012 [54]











USA Low H,EAC NR NR NR
van Vilsteren et
al., 2012 [56]
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USA Low IM,L,H,EAC 1 NR NR
Dulai et al.,
2013 [57]
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Gupta et al.,
2013 [35]
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Haidry et al.,
2013 [59]
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Korst et al.,
2013 [60]
RFA Full text CS Single Retro-
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Orman et al.,
2013 [42]




USA High L,H,EAC 1 Yes 1
Phoa et al.,
2013 [33]
RFA Full text CS Single Retro-
spective







USA Low IM,L,H,EAC 1 NR 2
Pasricha et al.,
2014 [32]






IM,L,H,EAC 1 or 2 No 1
Strauss et al.,
2014 [61]






EAC NR NR NR
Agoston et al.,
2015 [40]




USA Low EAC 1 NR 1
Cotton et al.,
2015 [43]






IM,L,H,EAC 1 Yes 1
Lada et al.,
2014 [62]




USA Low H,EAC 2 NR 1
Le Page et al.,
2016 [63]




Europe Low H,EAC NR NR NR
Phoa et al.,
2015 [64]
RFA Full text CS Multi Prospec-
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Europe Low IM,L,H,EAC 1 Yes 2
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Sensitivity analysis
A jackknife sensitivity analysis removing one study at a time did
not change the incidence of total recurrence in the remaining
studies within the RFA or SRER groups, indicating that no one
study had a significant impact on the results (data not shown).
Risk factors for recurrence
Risk factors for recurrence after RFA therapy were reported in 7
studies (6 manuscripts, 1 abstract) [32, 35, 40, 42, 44–46]. A
single study reported that the presence of erosive esophagitis
increased the risk of recurrence on multivariable regression a-
nalysis controlling for hiatal hernia length and presence of dys-
plasia [hazard ratio 15.41 (95%CI 1.65–144.33)] [45]. Most
studies found that age, gender, race, body mass index, baseline
histology before EET, BE length, NSAID use, hiatal hernia size,
and presence of a fundoplication were not associated with an
increased risk of recurrence. This is in contrast to a study by Pas-
richa et al. that reported older age [odds ratio (OR) 1.02 per
year, 95%CI 1.01–1.03], longer BE segment length (OR 1.10
per cm, 95%CI 1.06–1.15), and non-Caucasian race (OR 2.0,
95%CI 1.2–3.34) increased the risk of recurrence on multivari-
able regression analysis [32]. In addition, Lada et al. found that
recurrent dysplasia was more common in older patients, those
with longer follow-up, and those who underwent more total
procedures (including initial therapeutic interventions and sur-
veillance endoscopies) [46]. Similarly, Small et al. found that
the number of treatment sessions needed to achieve CE-IM in
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et al., 2004 [65]
EMR Full text CS Single Retro-
spective
Europe Low H,EAC NR No NR
Larghi et al.,
2007 [66]
EMR Full text CS Multi Retro-
spective
USA Low H,EAC NR No 1–2
Lopes et al.,
2007 [67]
EMR Full text CS Single Retro-
spective
Europe Low H,EAC NR No NR
Chennat et al.,
2009 [68]
EMR Full text CS Single Retro-
spective
USA Low H,EAC NR No 1–2
Brahmania
et al., 2010 [69]
EMR Full text CS Single Retro-
spective
Canada Low IM,L,H,EAC NR NR NR
Moss et al.,
2010 [70]




Low H,EAC NR No 1
Chung et al.,
2011 [26]




Low H,EAC NR No 1
Gerke et al.,
2011 [25]
EMR Full text CS Single Retro-
spective
USA Low L,H,EAC NR Yes NR
Anders et al.,
2014 [27]




Europe High L,H,EAC 2 No NR
Conio et al.,
2014 [71]
EMR Full text CS Single Retro-
spective
Europe Low H,EAC NR Yes NR
Konda et al.,
2014 [28]
EMR Full text CS Single Retro-
spective
USA Low L,H,EAC 1 Yes NR
Belghazi et al.,
2016 [72]
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EET=endoscopic eradication therapy, EGD=esophagogastroduodenoscopy, CR= complete remission, EMR=endoscopic mucosal resection, RFA= radiofrequency
ablation, CS= case series, IM= intestinal metaplasia, L = low grade dysplasia, H=high grade dysplasia, EAC=early adenocarcinoma, NR=not reported, RCT= random-
ized control trial.
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50 54.3 74 3.1 50 5 4 4 0 0
Alvarez Herrero
et al., 2011 [53]
26 66 80.8 11 20 2.4 8 8 0 0
Shaheen et al.,
2011 [30]
119 66 85.7 4.9 119 3.05 19 14 3 2
Vaccaro et al.,
2011 [36]
47 64.2 76.6 2 47 1.11 15 11 4 0
van Vilsteren et
al., 2011 [34]1
22 69 86.4 4 21 1.8 2 2 0 0
Caillol et al.,
2012 [54]
34 60 82.4 6.8 34 1 2 0 0 2
Gupta et al.,
2012 [55]
128 65.7 88.3 4.4 128 1.3 34 18 16 0
van Vilsteren et
al., 2012 [56]
24 68 83.3 8 20 1.2 0 0 0 0
Akiyama et al.,
2013 [45]
40 62.5 80 4.1 40 2.18 7 7 0 0
Dulai et al.,
2013 [57]
72 66.9 80.6 7.6 57 3.25 11 11 0 0
Ertan et al.,
2013 [58]
53 65.4 73.6 5.7 47 2.75 3 3 0 0
Gupta et al.,
2013 [35]
448 64 85 4.3 192 1.12 37 29 8 0
Haidry et al.,
2013 [59]
335 68.1 80.9 5.8 256 1.58 37 17 16 4
Korst et al.,
2013 [60]
53 59 69.8 3 53 1.5 14 14 0 0
Orman et al.,
2013 [42]
112 64.1 79.5 4 107 1.1 8 3 2 3
Phoa et al.,
2013 [33]
55 65 81.8 5 54 5.1 25 22 1 2
Shue et al.,
2013 [47]
42 61 71.4 3.5 42 1.17 11 11 0 0
Pasricha et al.,
2014 [32]
1634 61.7 74 4 NR NR 334 269 52 13
Strauss et al.,
2014 [61]
36 64 72.2 3.5 32 2 9 5 3 1
Agoston et al.,
2015 [40]
78 67.1 75.6 4.1 67 2.2 – – – 6
Cotton et al.,
2015 [43]
198 69.8 70.7 4.7 198 3 35 22 7 6
Lada et al.,
2014 [62]
57 66.2 87.7 5.1 57 2.95 16 4 12 0
E436 Fujii-Lau Larissa L et al. Recurrence of intestinal… Endoscopy International Open 2017; 05: E430–E449
Original article






























Le Page et al.,
2016 [63]
50 67 72 5 45 1.75 – – – 2
Phoa et al.,
2015 [64]
132 65 81 6 121 2.25 10 5 3 2
Small et al.,
2015 [44]
197 67.9 84.8 2.4 197 2.87 81 64 15 2
SRER group
Giovannini
et al., 2004 [65]
21 63 52.4 3.5 18 1.5 2 0 2 0
Larghi et al.,
2007 [66]
24 64.1 83.3 2.5 24 2.3 3 2 0 1
Lopes et al.,
2007 [67]
41 65.8 83.4 4.9 41 2.6 11 10 0 1
Chennat et al.,
2009 [68]
49 67 75.5 3.2 32 1.9 1 1 0 0
Brahmania
et al., 2010 [69]
22 67 100 5.5 18 2 4 0 4 0
Moss et al.,
2010 [70]
75 68 78.7 3.6 33 2.6 0 0 0 0
Chung et al.,
2011 [26]
77 65 83.1 2 73 1.4 5 2 3 0
Gerke et al.,
2011 [25]
41 67 78 3.2 32 2.1 3 3 0 0
van Vilsteren et
al., 2011 [34]1
25 68 84 4 25 2.1 3 2 0 1
Anders et al.,
2014 [27]
90 63 91.1 NR 81 5.4 37 32 2 3
Conio et al.,
2014 [71]
47 65 91.5 3 43 1.5 2 0 1 1
Konda et al.,
2014 [28]
86 67.5 NR 3.6 74 2.8 15 7 7 1
Belghazi et al.,
2016 [72]
73 64 87.6 3 73 6.33 17 16 0 1
Both SRER and RFA combined
Wani et al.,
2016 [51]
542 67 79.5 5.4 446 2.75 127 85 42 0
Waxman et al.,
2016 [73]
152 64.9 90.1 5 129 3.53 48 34 14
RFA= radiofrequency ablation, SRER= stepwise complete endoscopic resection, BE=Barrett’s esophagus, IM= intestinal metaplasia, EAC=early adenocarcinoma,
NR=not reported.
1 Randomized trial of RFA vs SRER, therefore the patient data was split into the corresponding groups.
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patients with HGD, but not EAC, had an increased risk of devel-
oping recurrent dysplasia, while older age and non-Caucasian
race had a higher risk of recurrent dysplasia [44]. Vacarro et al.
[36] found that BE length was significantly associated with in-
creased recurrence (P=0.03). Other risk factors identified by
Shue et al. that increased the risk of IM recurrence included
smoking (39.3% vs 0% among those with and without recur-
rence, P=0.006) and mean BMI (25.3 vs 29.8 among those
with and without recurrence, P=0.002) [47]. Only one study fo-
cused on recurrence post SRER and reported BE length as a pre-
dictor for IM and dysplasia on multivariable regression analysis
[OR 2.73 (95%CI 1.01–7.38)] [27].
Publication bias
Using Egger’s regression intercept, the two-tailed P value of
the publication bias for total recurrence and IM recurrence
among all studies was 0.14 and 0.46, respectively, suggesting
the lack of publication bias. The funnel plot for total recurrence
is shown in ▶Fig. 3. The P value for early neoplasia (EN) recur-
Study name Statistics for each study Rate and 95 % CI
 Rate Lower Upper
  limit limit p-Value 
Fleischer DE 2010 1.6 0.0 3.2 0.06
Alvarez Herrero L 2011 16.7 5.1 28.2 0.01
Shaheen NJ 2011 5.2 2.9 7.6 0.00
Vaccaro BJ 2011 28.8 14.2 43.3 0.00
van Vilsteren FGI 2011 5.3 0.0 12.6 0.16
Caillol F 2012 5.9 0.0 14.0 0.16
Gupta N 2012 20.4 13.6 27.3 0.00
van Vilsteren FGI 2012 2.0 0.0 7.7 0.48
Akiyama J 2013 8.0 2.1 14.0 0.01
Dulai PS 2013 5.9 2.4 9.4 0.00
Ertan A 2013 2.3 0.0 4.9 0.08
Gupta M 2013 17.2 11.7 22.8 0.00
Haidry RF 2013 9.1 6.2 12.1 0.00
Korst RJ 2013 17.6 8.4 26.8 0.00
Orman ES 2013 6.8 2.1 11.5 0.01
Phoa KN 2013 9.1 5.5 12.6 0.00
Shue P 2013 22.4 9.2 35.6 0.00
Pasricha S 2014 8.4 7.5 9.3 0.00
Strauss AC 2014 14.1 4.9 23.2 0.00
Cotton CC 2015 5.9 3.9 7.8 0.00
Lada MJ 2015 9.5 4.9 14.2 0.00
Phoa KN 2015 3.7 1.4 5.9 0.00
Small AJ 2015 14.3 11.2 17.4 0.00
Giovannini M 2004 7.4 0.0 17.7 0.16
Larghi A 2007 5.4 0.0 11.6 0.83
Lopes CV 2007 10.3 4.2 16.4 0.00
Chennat J 2009 1.6 0.0 4.9 0.32
Brahmania M 2010 11.1 0.2 22.0 0.05
Moss A 2010 0.6 0.0 2.2 0.48
Pouw RE 2010 4.6 2.6 6.7 0.00
Chung A 2011 4.9 0.6 9.2 0.03
Gerke H 2011 4.5 0.0 9.5 0.08
van Vilsteren FGI 2011- EMR 5.7 0.0 12.2 0.08
Anders M 2014 8.5 5.7 11.2 0.00
Conio M 2014 3.1 0.0 7.4 0.16
Konda VJA 2014 7.2 3.6 10.9 0.00




Incidence of total recurrence across all studies
▶ Fig. 2a Overall pooled incidence of any recurrence (intestinal metaplasia or dysplasia) after achieving complete eradication of intestinal
metaplasia following endoscopic eradication therapy using stepwise complete endoscopic resection or radiofrequency ablation with or with-
out focal endoscopic mucosal resection.
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rence was <0.001, suggesting the presence of a publication
bias in this subgroup.
Discussion
EET in BE patients at highest risk for progression to invasive
cancer (mucosal EAC, HGD and LGD) is a well-established and
effective treatment strategy that minimizes cancer risk and re-
duces the morbidity and mortality associated with EAC. This
practice has now been endorsed by gastrointestinal societal
guidelines and has replaced esophagectomy as the standard of
care for HGD and EAC confined to the mucosa [8, 48, 49]. While
the effectiveness of EET has been demonstrated in randomized
controlled trials and large observational studies, variable rates
of recurrence of IM and dysplasia have been reported post-
EET. A reliable estimate of the risk of recurrence after achieving
CE-IM is critical to establish surveillance guidelines (duration
and frequency of surveillance endoscopy), determine cost-ef-
fectiveness of EET, and ultimately educate physicians and pa-
tients before embarking on EET.
Study name Statistics for each study Rate and 95 % CI
 Rate Lower Upper
  limit limit p-Value 
Fleischer DE 2010 1.6 0.0 3.2 0.05
Alvarez Herrero L 2011 16.7 5.1 28.2 0.01
Shaheen NJ 2011 2.8 1.0 4.5 0.00
Vaccaro BJ 2011 21.1 8.6 33.5 0.00
van Vilsteren FGI 2011 5.3 0.0 12.6 0.16
Caillol F 2012 1.4 0.0 5.5 0.48
Gupta N 2012 10.8 5.8 15.8 0.00
van Vilsteren FGI 2012 2.0 0.0 7.7 0.48
Akiyama J 2013 8.0 2.1 14.0 0.01
Dulai PS 2013 5.9 2.4 9.4 0.00
Ertan A 2013 2.3 0.0 4.9 0.08
Gupta M 2013 13.5 8.6 18.4 0.00
Haidry RF 2013 4.2 2.2 6.2 0.00
Korst RJ 2013 17.6 8.4 26.8 0.00
Orman ES 2013 2.5 0.0 5.4 0.08
Phoa KN 2013 8.0 4.7 11.3 0.00
Shue P 2013 22.4 9.2 35.6 0.00
Pasricha S 2014 6.8 5.9 7.6 0.00
Strauss AC 2014 7.8 1.0 14.7 0.03
Cotton CC 2015 3.7 2.2 5.3 0.00
Lada MJ 2015 2.4 0.0 4.7 0.05
Phoa KN 2015 1.8 0.2 3.4 0.03
Small AJ 2015 11.3 8.5 14.1 0.00
Giovannini M 2004 1.8 0.0 6.9 0.48
Larghi A 2007 3.6 0.0 8.6 0.16
Lopes CV 2007 9.4 3.6 15.2 0.00
Chennat J 2009 1.6 0.0 4.9 0.32
Brahmania M 2010 1.4 0.0 5.2 0.48
Moss A 2010 0.6 0.0 2.2 0.48
Pouw RE 2010 3.9 2.1 5.8 0.00
Chung A 2011 2.0 0.0 4.7 0.16
Gerke H 2011 4.5 0.0 9.5 0.08
van Vilsteren FGI 2011- EMR 3.8 0.0 9.1 0.16
Anders M 2014 7.3 4.8 9.9 0.00
Conio M 2014 0.8 0.0 2.9 0.48
Konda VJA 2014 3.4 0.9 5.9 0.01




Incidence of IM recurrence across all studies
▶ Fig. 2b Overall pooled incidence of intestinal metaplasia after achieving complete eradication of intestinal metaplasia following endoscopic
eradication therapy using stepwise complete endoscopic resection or radiofrequency ablation with or without focal endoscopic mucosal re-
section.
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The results of this systematic review and meta-analysis de-
monstrate a pooled incidence rate for any recurrence, IM, and
dysplasia of 7.5%/100 PY (95%CI 6.1–9), 4.8%/100 PY (95%CI
3.8–5.9), and 2.0%/100 PY (95%CI 1.5–2.5), respectively
using EET treatment modalities (RFA with or without focal EMR
and SRER). In addition, the vast majority of recurrences were
amenable to repeat EET. In a recent systematic review and
meta-analysis, Krishnamoorthi and colleagues also reported
the risk of recurrence of IM, dysplasia, and HGD/EAC in patients
undergoing RFA and recurrence rates after use of all endoscopic
modalities [50]. While the primary results were similar, the cur-
rent study focused primarily on contemporary EET therapies
and also compared recurrence rates between RFA and SRER.
Similar to the above study, the current study with updated
Study name Statistics for each study Rate and 95 % CI
 Rate Lower Upper
  limit limit p-Value 
Fleischer DE 2010 0.2 0.0 0.8 0.48
Alvarez Herrero L 2011 1.0 0.0 3.9 0.48
Shaheen NJ 2011 1.4 0.2 2.6 0.03
Vaccaro BJ 2011 7.7 0.2 15.2 0.05
van Vilsteren FGI 2011 1.3 0.0 4.9 0.48
Caillol F 2012 5.9 0.0 14.0 0.16
Gupta N 2012 9.6 4.9 14.3 0.00
van Vilsteren FGI 2012 2.0 0.0 7.7 0.48
Akiyama J 2013 0.6 0.0 2.2 0.48
Dulai PS 2013 0.3 0.0 1.0 0.48
Ertan A 2013 0.4 0.0 1.5 0.48
Gupta M 2013 3.7 1.1 6.3 0.01
Haidry RF 2013 4.9 2.8 7.1 0.00
Korst RJ 2013 0.6 0.0 2.4 0.48
Orman ES 2013 4.2 0.5 8.0 0.03
Phoa KN 2013 1.1 0.0 2.3 0.08
Shue P 2013 1.0 0.0 3.8 0.48
Pasricha S 2014 1.6 1.2 2.0 0.00
Strauss AC 2014 6.3 0.1 12.4 0.05
Agoston AT 2015 4.1 0.8 7.3 0.01
Cotton CC 2015 2.2 1.0 3.4 0.00
Lada MJ 2015 7.1 3.1 11.2 0.00
Le Page PA 2015 2.5 0.0 6.1 0.16
Phoa KN 2015 1.8 0.2 3.4 0.03
Small AJ 2015 3.0 1.6 4.4 0.00
Giovannini M 2004 7.4 0.0 17.7 0.16
Larghi A 2007 1.8 0.0 5.4 0.32
Lopes CV 2007 0.9 0.0 2.8 0.32
Chennat J 2009 0.8 0.0 3.1 0.48
Brahmania M 2010 11.1 0.2 22.0 0.05
Moss A 2010 0.6 0.0 2.2 0.48
Pouw RE 2010 0.7 0.0 1.5 0.08
Chung A 2011 2.9 0.0 6.3 0.08
Gerke H 2011 0.7 0.0 2.8 0.48
van Vilsteren FGI 2011- EMR 1.9 0.0 5.6 0.32
Anders M 2014 1.1 0.1 2.1 0.03
Conio M 2014 3.1 0.0 7.4 0.16
Konda VJA 2014 3.9 1.2 6.5 0.01




Incidence of dysplasia recurrewnce across all studies
▶ Fig. 2c Overall pooled incidence of early neoplasia (EN) after achieving complete eradication of intestinal metaplasia following endoscopic
eradication therapy using stepwise complete endoscopic resection or radiofrequency ablation with or without focal endoscopic mucosal re-
section.
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search results noted substantial heterogeneity. Another study
that provided a recurrence estimate was a study by Orman et
al. that determined the efficacy and durability of RFA for pa-
tients with dysplastic and non-dysplastic BE. That study report-
ed the proportion of patients with recurrence of IM after suc-
cessful CE-IM with RFA therapy and quoted a point estimate of
13% (95%CI 9–18%) [31]. However, reporting recurrence rate
per patient-year of follow-up (accounting for follow-up dura-
tion) is a more stable and meaningful outcome.
The results of this study raise the important issue with re-
gard to the optimal EET strategy (SRER vs RFA with or without
EMR) with regard to recurrence of IM and dysplasia. Patients in
the RFA group had higher overall and IM recurrence rates com-
pared to patients treated with SRER; however, there was no dif-
ference between the two groups with regard to recurrence of
dysplasia. The authors acknowledge that any direct comparison
between RFA and SRER is biased as only one study directly com-
pared these two strategies in a randomized controlled trial. We
emphasize that any comparison between RFA and SRER is indir-
ect based on the rates of recurrence in each arm obtained by
combining observational studies. Although several studies
have confirmed the effectiveness and durability of SRER, this
treatment approach is associated with a high stricture rate
[27–29]. In a multicenter randomized controlled trial compar-
ing these two treatment approaches, a higher stricture rate was
reported in patients treated with SRER compared to patients
treated with focal EMR followed by RFA (88% vs 14%, P<
0.001) with no difference in efficacy indicators of CE-IM and
CE-D [34]. This justifies the current strategy of focal EMR for
visible lesions followed by ablation of the residual Barrett’s seg-
ment for optimal treatment of BE related neoplasia [8, 48, 49].
In addition, the studies evaluating SRER limited the length of
BE in the included patients and, given that many studies identi-
fy BE length as a risk factor for recurrence, the lower recurrence
rate (overall and IM) in the SRER group may be confounded by
BE length. Whether there is a subgroup of BE-related neoplasia
patients (multifocal disease, diffuse nodularity) more likely to
benefit from SRER needs to be evaluated in future studies. Im-
provement in prevention of stricture formation post-SRER is
also required before this treatment strategy can be recommen-
ded as a primary treatment modality.
This systematic review highlights the variable rates of recur-
rence reported in the literature, an important take-home mes-
sage of this study. The purported factors for this include study
design (prospective vs retrospective), participating centers
(tertiary care vs community practices), sample size, variability
in study inclusion criteria (histologic grades of BE), treatment
and surveillance protocol, duration of follow-up, and defini-
tions of CE-IM and recurrence (whether IM at or just below the
neo-squamocolumnar junction is included in the numerator of
patients with recurrences). Although some studies reported on
subsquamous IM recurrence and recurrence of the cardia, the
significance of these findings was unclear. With the low number
of studies focusing on these outcomes, this was not a focus of
the manuscript. Several factors in the subgroup analyses were
associated with a significant difference in incidence rates; how-
ever, none completely account for the heterogeneity noted in
this meta-analysis. For example, in the RFA group, prospective
studies were associated with a lower incidence of total, IM, and
dysplasia recurrence rates compared to retrospective studies
and a higher dysplasia recurrence rate was reported in trials
conducted at tertiary care centers. This may be related to in-
herent limitations associated with retrospective and multicen-
ter studies (lack of standardized definitions, treatment and sur-
veillance protocol). Contrary to previous studies, recurrence of
dysplasia was higher in BE patients with length <3 cm. The rea-
Funnel plot for publication bias of total recurrence
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▶ Fig. 3 Funnel plot for publication bias on the incidence of total
recurrence among all studies.
▶ Table 3 Incidence of recurrence after achieving CE-IM following EET.
Total recurrence IM recurrence Dysplasia recurrence
No. of
studies








Incidence per 100 PY
(95%CI)
Overall 361 6.8 (5.4–8.1) 351 4.4 (3.4–5.4) 381 1.6 (1.1–2.1)
RFA 23 8.6 (6.7–10.5) 23 5.8 (4.3–7.3) 25 1.9 (1.3–2.5)
SRER 13 4.9 (3–6.8) 12 3.3 (2–4.7) 13 1.2 (0.4–1.9)
CE-IM= complete eradication of intestinal metaplasia, EET= endoscopic eradication therapy, RFA= radiofrequency ablation, SRER= stepwise complete endoscopic
resection, IM= intestinal metaplasia, PY=patient-years; Dysplasia recurrence includes dysplasia and EAC.
1 One study compared RFA to SRER. Its data is separated into each group, making the overall number of studies one less than the total RFA and SRER studies com-
bined.
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Fleischer et al., 2010 [52] 4 4 0 0 NR
Alvarez Herrero et al., 2011 [53] 8 8 0 0 NR
Shaheen et al., 2011 [30] 19 14 3 2 RFA
Vaccaro et al., 2011 [36] 15 11 4 0 RFA, EMR
van Vilsteren et al., 2011 [34]1 2 2 0 0 NR
Caillol et al., 2012 [54] 2 0 0 2 NR
Gupta et al., 2012 [55] 34 18 16 0 APC/RFA, EMR
van Vilsteren et al., 2012 [56] 0 0 0 0 No recurrence
Akiyama et al., 2013 [45] 7 7 0 0 NR
Dulai et al., 2013 [57] 11 11 0 0 RFA
Ertan et al., 2013 [58] 3 3 0 0 All three underwent surgery
Gupta et al., 2013 [35] 37 29 8 0 NR
Haidry et al., 2013 [59] 37 17 16 4 NR
Korst et al., 2013 [60] 14 14 0 0 RFA
Orman et al., 2013 [42] 8 3 2 3 RFA
Phoa et al., 2013 [33] 25 22 1 2 NR
Shue et al., 2013 [47] 11 11 0 0 NR
Pasricha et al., 2014 [32] 334 269 52 13 NR
Strauss et al., 2014 [61] 9 5 3 1 RFA
Agoston et al., 2015 [40] – – – 6 Unclear as primary failure not
differentiated from recurrences
Cotton et al., 2015 [43] 35 22 7 6 NR
Lada et al., 2014 [62] 16 4 12 0 NR
Le Page PA 2016 [63] – – – 2 APC/RFA, EMR
Phoa et al., 2015 [64] 10 5 3 2 APC, EMR
Small et al., 2015 [44] 81 64 15 2 Treated endoscopically but did
not specify how
Giovannini et al., 2004 [65] 2 0 2 0 NR
Larghi et al., 2007 [66] 3 2 0 1 NR
Lopes et al., 2007 [67] 11 10 0 1 NR
Chennat et al., 2009 [68] 1 1 0 0 NR
Brahmania et al., 2010 [69] 4 0 4 0 All recurrences were LGD and
under surveillance
Moss et al., 2010 [70] 0 0 0 0 No recurrence
Chung et al., 2011 [26] 5 2 3 0 EMR
Gerke et al., 2011 [25] 3 3 0 0 RFA, EMR
van Vilsteren et al., 2011 [34]1 3 2 0 1 NR
Anders et al., 2014 [27] 37 32 2 3 APC, EMR
Conio et al., 2014 [71] 2 0 1 1 NR
Konda et al., 2014 [28] 15 7 7 1 EMR
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son for this finding is unclear. Subgroup analyses provided no
evidence that overall recurrence rates are higher in patients
with BE related neoplasia compared to those with non-dysplas-
tic BE. Consistent with the results from the US RFA Registry
[32], there was no difference in recurrence rates based on the
definition of CE-IM (CE-IM defined by one or two successive
negative endoscopies).
There are limitations of this systematic review and meta-a-
nalysis that merit discussion. One inherent limitation of the
study design is the quality of the individual studies. The major-
ity of the studies that met the inclusion criteria were of low to
moderate quality, with only three studies meeting the criteria
for high quality. This is predominantly because recurrence after
EET was often a secondary analysis rather than the primary end
point of the study. Another major limitation is the substantial
heterogeneity noted in the assessment of recurrence rates.
This may be related to patient characteristics, significant varia-
bility in the baseline pathology of included patients (proportion
of included patients with HGD/early EAC), endoscopic surveil-
lance intervals, surveillance biopsy protocols, confirmation by
a dedicated gastrointestinal pathologist, and variability in defi-
nition of recurrence between each study. This was addressed by
using strict inclusion and exclusion criteria and a priori sub-
group analyses to explore sources of heterogeneity. However,
the authors acknowledge that the substantial heterogeneity
tempers the confidence level associated with the estimates of
recurrence reported in this study and the precision of these es-
timates may change as data from large prospective multicenter
trials become available.
The authors acknowledge that it would be ideal to conduct a
time-to-event analysis accounting for individual patient data
and patients lost to follow-up.However, these data were re-
ported in few studies thus precluding this analysis. This study
also highlights the fact that only a limited number of studies re-
port on the risk factors associated with recurrence, and they
comprise only a small number of overall recurrences, limiting
our ability to perform multivariable regression analysis. Hence,
only a descriptive analysis of risk factors was provided in this
study. The associations between the presence of erosive esoph-
agitis, older age, non-Caucasian race, pretreatment BE length,
and recurrence of IM and dysplasia need to be explored and
confirmed in future studies. The generalizability of these esti-
mates is limited by the fact that most of the included studies
were conducted at tertiary care centers. Future studies need
to clarify if differences in technique and protocols, for instance,
the routine performance of circumferential RFA at the gastro-
esophageal junction (location of most recurrences) at each
RFA session, regardless of the presence of visible BE, impact
the durability of EET. Similarly, differences in acid suppressive
regimens need to be correlated with the likelihood of recur-
rence of IM and dysplasia. This study did not address the dur-
ability of other ablative techniques such as argon plasma coag-
ulation but focused on the most widely used techniques.
Finally, temporality of recurrence after achieving CE-IM can-
not be established with the available data in published reports.
Although surveillance post-CE-IM is uniformly recommended,
surveillance intervals suggested by current guidelines [8] are
largely driven by expert opinion and low quality evidence. Fu-
ture prospective studies need to provide guidance on current
surveillance strategies post CE-IM. The strengths of this study
include the use of strict study definitions and inclusion criteria,
and provision of point estimates for incidence of recurrence for
IM and dysplasia per patient-year for contemporary EET modal-
ities.
In conclusion, this systematic review highlights the variable
rates of recurrence reported in the literature. The results of this
meta-analysis report the incidence rates of recurrence of IM
and dysplasia after successful CE-IM in patients with BE post-
EET. The vast majority of recurrences were without dysplasia
and could be managed with repeat EET, adding credence to
the current strategy of EET for management of BE-related neo-
plasia. This study emphasizes the importance of routine long-
term endoscopic surveillance following EET and highlights the
need to discuss these recurrence estimates with patients be-
fore embarking on EET. Future prospective studies that use
standardized definitions for study end points and focus on re-
currence risk as the primary outcome are required to more pre-
cisely define the annual recurrence risk and the predictors asso-
ciated with recurrence. This will allow for evidence-based re-
commendations with regard to surveillance endoscopic and
biopsy protocols after successful EET of BE-related neoplasia
patients with the goal of stopping or reducing the frequency
of surveillance in low risk individuals and enrolling high risk pa-
tients in an intensive surveillance protocol.










Belghazi et al., 2016 [72] 17 16 0 1 Esophagectomy for T1b cancer
Wani et al., 2016 [51] 127 85 42 NR
Waxman et al., 2016 [73] 48 34 14 NR
NR=not reported, RFA= radiofrequency ablation, EMR=endoscopic mucosal resection, APC=argon plasma coagulation, LGD= low grade dysplasia.
1 Randomized trial of RFA vs SRER, therefore the patient data was split into the corresponding groups.
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EGD=esophagogastroduodenoscopy, IM= intestinal metaplasia, EN=early neoplasia, CE= complete eradication, BE=Barrett’s esophagus, PY=patient-years, RFA=
radiofrequency ablation.
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BE length > 3 cm 0.51 0.46 0.87

















EGD=esophagogastroduodenoscopy, IM= intestinal metaplasia, EN=early neoplasia, CE= complete eradication, BE=Barrett’s esophagus, PY=patient-years, SRER=
stepwise complete endoscopic resection.
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